Equillium, Inc. (EQ) company profile
Close on Nov 17, 2026Market cap $76.72MP/E –Yield –
About Equillium
Pharmaceutical Preparations, SIC 2834
Equillium, Inc. is a biotechnology company focused on developing novel therapeutics for severe autoimmune and inflammatory disorders. Its pipeline includes EQ504, an aryl hydrocarbon receptor modulator being developed for the treatment of ulcerative colitis and other gastrointestinal conditions, with potential expansion into inflammatory lung diseases. The company is also evaluating EQ302, an orally administered bi-specific inhibitor of IL-15 and IL-21 designed to address gastrointestinal disorders such as celiac disease. Equillium focuses on addressing unmet medical needs across gastroenterology, dermatology, and pulmonology.
The company conducts its operations in the United States, utilizing dedicated office and laboratory spaces to support its research and drug development activities. Its research efforts and strategic corporate operations are based in California, with presence in San Diego and La Jolla. Equillium's principal executive offices and corporate headquarters are located in La Jolla, California.
Summary of the business section of Equillium's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Equillium, Inc.
- Headquarters
- La Jolla, CA
- Address
- 2223 Avenida De La Playa, Suite 105 92037
- Phone
- (858) 412-5302
- Website
- equilliumbio.com
- Employees
- 14, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- KPMG LLP, San Diego, California
Stock & identifiers
- Ticker
- EQ
- Exchange
- Nasdaq
- IPO date
- Oct 12, 2018
- Shares outstanding
- 63M, Aug 7, 2026
- Public float
- $7.10M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- SEC CIK
- 1746466
- CUSIP
- 29446K106
- ISIN
- US29446K1060
- FIGI
- BBG00LSL8C10
- Share class FIGI
- BBG00LSL8C29
- LEI
- 549300OC7SSPSNNGHE64
- EIN
- 82-1554746
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Daniel Bradbury | CHAIRMAN, Director | 3,711,995 |
| Bruce D. Steel | Chief Executive Officer, Director | 3,711,995 |
| Stephen Connelly | President and CSO | 762,025 |
| Christine Zedelmayer | Sr. Vice President and COO | 62,586 |
| Penny Tom | Principal Accounting Officer | 65,000 |
| Jason A. Keyes | Chief Financial Officer | 126,633 |
| Martha J. Demski | Director | 23,799 |
| Mark Pruzanski | Director | 23,799 |
| Charles Douglas McDermott | Director | 23,799 |
| Barbara Troupin | Director | – |
| Bala S. Manian | Director | 23,799 |
| Peter Colabuono | Director | – |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $4.26M | $4.48M | $2.40M | $146 | – |
| FY2024 | $684.39K | $754.07K | $512.83K | $71 | – |
| FY2023 | $1.35M | $1.03M | $806.38K | $68 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Option awards | Incentive pay | Total | vs. prior year |
|---|---|---|---|---|---|---|
| Bruce D. Steel Chief Executive Officer | $519.23K | $353.51K | $3.02M | $361.80K | $4.26M | +522% |
| Stephen Connelly, Ph.D. President and Chief Scientific Officer | $455.17K | $271.40K | $1.78M | $200.00K | $2.70M | +420% |
| Christine Zedelmayer Chief Operating Officer | $441.29K | $175.00K | $1.29M | $194.00K | $2.10M | +315% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Oct 12, 2018
- Offer price
- $14.00
- Securities offered
- 4,670,000
- Gross proceeds
- $65.38M
- Exchange
- Nasdaq
- Lock-up ends (est.)
- Apr 10, 2019
“The initial public offering price of our common stock is $14.00 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we employed 14 employees, of which 13 were full-time employees, who were engaged in research and development activities, operations, finance, business development or administration.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Oct 24, 2025 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Oct 6, 2025 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Jun 13, 2025 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Dec 13, 2024 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Jul 23, 2024 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Oct 5, 2023 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Apr 6, 2023 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Oct 27, 2022 | Merger | Registration of securities for a merger or exchange offer (S-4) |
| Feb 16, 2022 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Oct 12, 2018 | IPO | Initial public offering priced (424B4 prospectus) |
| Oct 5, 2018 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?